Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

Fed Chair Powell's dovish Jackson Hole speech sparks a market rally, while tech dips and earnings drive individual stocks ...

The weight-loss drug Wegovy just got FDA approval to treat a common and serious liver condition known as MASH (Metabolic ...

“Most users tolerate GLP-1 medications like Ozempic without serious oral health issues, but a subset experience notable side ...

COMMENT: The monthly cost of a private prescription exceeding £300 from next month is worrying news for the half a million ...

Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

So the, the question we're investigating in this study is whether the use of GLP-1 receptor agonists, which is *** medication ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...